DISEASE SCANNER
Global Incurable Diseases Tracker
Progressive Supranuclear Palsy (PSP)
A rare, rapidly progressive neurodegenerative disorder affecting movement, balance, speech, swallowing, and vision. Characterized by tau protein accumulation. Often misdiagnosed as Parkinson's disease. Average survival 5-7 years from onset.
20.0K
15
Symptoms
Treatment Options
Risk Factors
Diagnostic Methods
- 1Neurological examination
- 2MRI/CT imaging
- 3EEG
- 4EMG/NCV
- 5Lumbar puncture
- 6Genetic testing
- 7Neuropsychological testing
Prognosis
Rapidly progressive parkinsonism with poor response to levodopa. Median survival 5-7 years from symptom onset. Early falls and vertical gaze palsy are characteristic. Aspiration pneumonia is common cause of death. No disease-modifying therapy exists. Multidisciplinary supportive care essential. Differential diagnosis from Parkinson's disease is important for prognosis and counseling. Frontal lobe dysfunction and pseudobulbar affect are common.
Prevention
- Head protection
- Cardiovascular health
- Cognitive stimulation
- Physical exercise
- Healthy diet
- Avoidance of toxins
- Regular monitoring
Research Status
No disease-modifying treatment. Supportive care only. Tau immunotherapy trials ongoing (Tilavonemab discontinued). Amantadine may provide modest benefit. Multidisciplinary care essential.
Affected Countries
Sources
- https://www.ncbi.nlm.nih.gov/books/NBK539800
- https://www.ncbi.nlm.nih.gov/books
- https://www.mayoclinic.org/diseases-conditions
- https://rarediseases.org/rare-diseases
Medical Disclaimer
This information is for educational purposes only. Always consult healthcare professionals for medical advice, diagnosis, and treatment.